These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 19166682

  • 1. Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    McKay RG, Dada MR, Mather JF, Mennet RR, Murphy DJ, Maloney KW, Hirst JA, Kiernan FJ.
    Am J Cardiol; 2009 Feb 01; 103(3):316-21. PubMed ID: 19166682
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals.
    Coleman CI, McKay RG, Boden WE, Mather JF, White CM.
    Clin Ther; 2006 Jul 01; 28(7):1054-62. PubMed ID: 16990084
    [Abstract] [Full Text] [Related]

  • 3. Prospective multicenter randomized trial comparing physician versus patient transfer for primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction.
    Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, Liao ML, Zhang JS, Hu J, Yang ZK, Shen WF.
    Chin Med J (Engl); 2008 Mar 20; 121(6):485-91. PubMed ID: 18364130
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Sinno MC, Khanal S, Al-Mallah MH, Arida M, Weaver WD.
    Am Heart J; 2007 Apr 20; 153(4):579-86. PubMed ID: 17383297
    [Abstract] [Full Text] [Related]

  • 5. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S, Mezyński G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachórzewska-Gajewska H, Sawicki Z, Poniatowski B, Korecki J, Musiał WJ.
    Kardiol Pol; 2006 Aug 20; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [Abstract] [Full Text] [Related]

  • 6. Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study.
    Zhang Q, Zhang RY, Qiu JP, Jin HG, Zhang JF, Wang XL, Jiang L, Liao ML, Hu J, Ding FH, Zhang JS, Shen WF.
    Chin Med J (Engl); 2009 Mar 20; 122(6):636-42. PubMed ID: 19323926
    [Abstract] [Full Text] [Related]

  • 7. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
    Berrocal DH, Cohen MG, Spinetta AD, Ben MG, Rojas Matas CA, Gabay JM, Magni JM, Nogareda G, Oberti P, Von Schulz C, Doval H, Bazzino OO, Cagide A, Oliveri R, Grinfeld LR.
    Am Heart J; 2003 Dec 20; 146(6):E22. PubMed ID: 14661011
    [Abstract] [Full Text] [Related]

  • 8. Primary percutaneous transluminal coronary intervention compared with intravenous thrombolysis in patients with ST segment elevation myocardial infarction.
    Tungsubutra W, Tresukosol D, Krittayaphong R, Panchavinnin P, Phankingtongkhum R, Chotnaiwattarakul C.
    J Med Assoc Thai; 2007 Apr 20; 90(4):672-8. PubMed ID: 17487120
    [Abstract] [Full Text] [Related]

  • 9. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun 20; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 10. Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis).
    Shavelle DM, Rasouli ML, Frederick P, Gibson CM, French WJ, National Registry of Myocardial Infarction Investigators.
    Am J Cardiol; 2005 Nov 01; 96(9):1227-32. PubMed ID: 16253587
    [Abstract] [Full Text] [Related]

  • 11. ST-elevation myocardial infarction mortality in a major academic center "on-" versus "off-" hours.
    Cubeddu RJ, Cruz-Gonzalez I, Kiernan TJ, Truong QA, Rosenfield K, Leinbach RC, Cadigan ME, Pomerantsev EV, Palacios IF.
    J Invasive Cardiol; 2009 Oct 01; 21(10):518-23. PubMed ID: 19805838
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ, National Registry of Myocardial Infarction-4.
    Am J Cardiol; 2006 Nov 01; 98(9):1125-31. PubMed ID: 17056312
    [Abstract] [Full Text] [Related]

  • 13. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
    Dobrzycki S, Kralisz P, Nowak K, Prokopczuk P, Kochman W, Korecki J, Poniatowski B, Zuk J, Sitniewska E, Bachorzewska-Gajewska H, Sienkiewicz J, Musial WJ.
    Eur Heart J; 2007 Oct 01; 28(20):2438-48. PubMed ID: 17884846
    [Abstract] [Full Text] [Related]

  • 14. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G, Marino P.
    Am J Emerg Med; 2009 Jul 01; 27(6):683-90. PubMed ID: 19751625
    [Abstract] [Full Text] [Related]

  • 15. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E, ExTRACT-TIMI 25 Investigators.
    J Am Coll Cardiol; 2007 Jun 12; 49(23):2238-46. PubMed ID: 17560287
    [Abstract] [Full Text] [Related]

  • 16. Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital.
    Le May MR, Davies RF, Dionne R, Maloney J, Trickett J, So D, Ha A, Sherrard H, Glover C, Marquis JF, O'Brien ER, Stiell IG, Poirier P, Labinaz M.
    Am J Cardiol; 2006 Nov 15; 98(10):1329-33. PubMed ID: 17134623
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction.
    Mehta RH, Sadiq I, Goldberg RJ, Gore JM, Avezum A, Spencer F, Kline-Rogers E, Allegrone J, Pieper K, Fox KA, Eagle KA, GRACE Investigators.
    Am Heart J; 2004 Feb 15; 147(2):253-9. PubMed ID: 14760322
    [Abstract] [Full Text] [Related]

  • 18. Primary coronary angioplasty in patients with ST segment elevation acute myocardial infarction and diabetes.
    Dudek D, Mielecki W, Wizimirski M, Rakowski T, Dziewierz A, Sorysz D, Tomala M, Zorkun C, Zmudka K, Dubiel JS.
    Kardiol Pol; 2004 Sep 15; 61(9):232-41; discussion 242. PubMed ID: 15531935
    [Abstract] [Full Text] [Related]

  • 19. Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction.
    Hiew C, Williams T, Hatton R, Narasimhan S, O'Connor S, Baker F, McElduff P, Attia J, Collins N.
    J Invasive Cardiol; 2010 Jun 15; 22(6):273-7. PubMed ID: 20516507
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of rescue angioplasty for ST-elevation myocardial infarction with high utilization rates of glycoprotein IIb/IIIa inhibitors.
    Shugman IM, Hsieh V, Cheng S, Parikh D, Tobing D, Wouters N, van der Vijver R, Lo Q, Rajaratnam R, Hopkins AP, Lo S, Leung D, Juergens CP, French JK.
    Am Heart J; 2012 Apr 15; 163(4):649-56.e1. PubMed ID: 22520531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.